CAPRICOR THERAPEUTICS INC (CAPR)
Health Care · Biotechnology · NASDAQ
A clinical-stage biotechnology company developing novel cell and exosome-based therapies for Duchenne muscular dystrophy and other rare diseases.
What CAPRICOR THERAPEUTICS INC does
Capricor Therapeutics is a biotechnology company focused on the development of cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with high unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy designed to address skeletal and cardiac muscle complications in DMD patients. The company also leverages a proprietary exosome platform, StealthX, to explore therapeutic applications for various conditions.
Recent developments
In July 2026, the FDA's advisory committee voted against the effectiveness of Deramiocel for the treatment of DMD-related cardiomyopathy, though the company continues to work with the FDA on a path to approval. Additionally, the company is engaged in legal action to rescind its U.S. distribution agreement with Nippon Shinyaku, with arbitration expected to begin in the fall of 2026. The company recently published Phase 3 HOPE-3 trial results in The Lancet, which demonstrated a statistically significant slowing of upper limb disease progression.
From CAPRICOR THERAPEUTICS INC's filing of 2026-08-14.
Themes: Duchenne muscular dystrophy (DMD), Cell therapy, Exosome therapeutics, Rare diseases, Gene regulation / RNA biology
Fundamentals
- Price$8.01 as of 2026-10-08 close
- Market cap$466M as of 2026-08-13 (share count; price 2026-10-08)
- 1-year return+7.1% 2025-10-08 close $7.48 → 2026-10-08 close $8.01
- P/En/a negative earnings
- ROE-34.4% FY2025, SEC XBRL
- Debt / equity0.02 as of 2026-09-03
- Beta1.10 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CAPR compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAPRICOR THERAPEUTICS INC looks technically
CAPRICOR THERAPEUTICS INC (CAPR) is trading 64.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 49 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day low about 3 trading days ago. It is 80.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 64.1% below its 200-day average, the long-term trend line — a long-term downtrend | -64.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.57 | $7.57 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $22.32 | $22.32 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 10.72. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 49 trading days ago — a "death cross", a bearish long-term signal | 49 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($7.37 to $10.72) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 19.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.37 | $40.37 |
|---|---|---|
| From the 52-week high | it is 80.2% below its 52-week high (its highest price of the past year) | -80.2% |
| Above the 52-week low | it is 170.6% above its 52-week low (its lowest price of the past year) | +170.6% |
| Below the 52-week high | it is 80.2% below its highest point of the past year | 80.2% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $3500.00 (set on 2007-10-24) | $3500.00 |
| Given back of the 52-week move | over the past year its closes ranged ($3.85 to $35.34), and it has recovered only a small part of its fall from last year’s high — 13% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $23.31 to $24.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.2% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 1.3% below a resistance level at $8.12 — a price it turned at three times since 2025-04-09, most recently on 2026-09-10. Since 2024-10-08 it has 2 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $0.88 (set on 2020-03-12) | $0.88 |
| Above the all-time low | it is 810.2% above its all-time low | +810.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8372 between its high and its low — about 10.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8372 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.68 and $9.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.68 – $8.65 – $9.61 |
| Typical daily range (% of price) | its price moves about 10.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.4% |
| Stretch from the 200-day average | it is trading 17.1 daily ranges below its 200-day average price (64.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 17.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.7% |
|---|---|---|
| Open gap | it gapped 2.2% below the previous close 3 sessions ago and has not traded back through the level it left behind at 8.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.2% |
| Gap filled | a 2.7% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.6 percentage points (the stock lost 11.6% while the market gained 1.0%) | -12.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 67.8 percentage points (the stock lost 64.0% while the market gained 3.8%) | -67.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 92.2 percentage points (the stock lost 74.7% while the market gained 17.5%) | -92.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.9 percentage points (the stock gained 7.1% while the market gained 15.0%) | -7.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 114.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 40% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $13.24 — a volume-weighted average of daily closes over 193 sessions, not a true tick-by-tick VWAP. | -39.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-13 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $7.81 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | +2.5% |
Price levels it has turned at before
CAPR last closed at $8.01 on 2026-10-08. Since 2024-10-08 it has turned at 2 prices below its last close and 10 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.12 | Resistance | 1.3% above the last close | turned there three times · 2025-04-09 to 2026-09-10 |
| $9.48 | Resistance | 18.4% above the last close | turned there twice · 2025-06-03 to 2025-08-08 |
| $6.23 | Support | 22.2% below the last close | turned there twice · 2025-05-09 to 2025-07-21 |
| $6.01 | Support | 24.9% below the last close | turned there four times · 2025-06-20 to 2026-08-21 |
| $11.61 | Resistance | 45.0% above the last close | turned there three times · 2025-03-18 to 2025-06-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $10.72.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-17.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.30 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$27.00 range $7.00 – $54.00; median $25.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CAPR
- Consensus EPS estimate-$0.42 next reporting period, as of 2026-10-07
- Estimate change, 30 days$0.00 from -$0.42, on 2026-09-02, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to obtain FDA approval for Deramiocel or significant delays in the regulatory process, including following negative Advisory Committee outcomes.","Ongoing legal disputes with contractual partners (e.g., Nippon Shinyaku) that could impact commercialization, resource allocation, and strategy.","Dependence on a single lead product candidate and the need for significant additional capital to reach commercialization and profitability."]
What changed in the latest 10-Q
AI-assisted comparison of CAPR's 10-Q filed 2026-08-14 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: "with a current Prescription Drug User Fee Act (\u201cPDUFA\u201d) target action date of August 22, 2026" describing the PDUFA date as current.
- Newer filing adds: "Capricor has administered approximately 1,300 intravenous infusions across our clinical program to over 200 patients with DMD in three separate clinical trials."
- Newer filing adds: "In late 2024, we completed our submission of a BLA to the FDA seeking approval of Deramiocel for the treatment of DMD. The FDA accepted the BLA for review, granted Priority Review, and assigned a PDUFA target action date of August 31, 2025. In July 2025, we received a Co" (new BLA submission history section, truncated in provided text).
- Removed:
- Older filing includes: "If approved and if our litigation against NS Pharma, Inc. and Nippon Shinyaku Co., Ltd. (collectively, \u201cNS\u201d) is successful, we intend to commercialize Deramiocel in the United States directly or through distributors, and we may also seek commercialization through strategic partners in other select international markets." This sentence is absent from newer filing.
- Older filing includes: "Our development efforts for Deramiocel for the treatment of DMD have progressed through multiple clinical studies, and we continue activities to support regulatory review and potential approval in the United States, as well as commercialization preparation, if approved." This paragraph is absent from newer filing.
- Reworded:
- Older filing describes Deramiocel as "a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD"; newer filing describes it as "a cell therapy aimed to treat the skeletal and cardiac muscle complications associated with DMD."
- Older filing: "including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline"; newer filing: "including many patients who are non-ambulatory and experiencing progressive skeletal and cardiac muscle decline" (word order changed).
- Notes:
- The newer filing text is truncated mid-sentence in the BLA section, limiting complete comparison of the remaining text.
- The older filing text is truncated mid-sentence in the clinical studies list, limiting complete comparison of the remaining text.
- Only the provided section excerpts were compared; other changes in the filings outside these excerpts are not reflected.
Risk Factors
- Added:
- Newer filing adds a new risk factor heading: 'The negative vote of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee is expected to have a significant impact on Deramiocel’s approvability in the U.S. for the treatment of cardiomyopathy in patients with DMD.'
- Newer filing adds a new paragraph describing the July 29, 2026 FDA Advisory Committee vote (3 in favor, 9 against, no abstentions) on Deramiocel effectiveness for cardiomyopathy in DMD patients.
- Newer filing adds that the voting question addressed a narrower indication than proposed and did not include a vote on the HOPE-3 primary endpoint of upper limb function or the overall benefit-risk profile.
- Newer filing adds that the company plans to submit an amendment to its BLA, which the FDA has indicated it is willing to review.
- Newer filing adds that the company does not know how long the FDA decision will take, and that the FDA may issue a complete response letter rejecting the amended BLA or further delay approval.
- Newer filing adds that the company withdrew the motion for preliminary injunction without prejudice, having determined that resolving the dispute in arbitration following the FDA's decision would give the parties a more complete regulatory record.
- Newer filing adds that the company estimates arbitration to begin this fall.
- Newer filing adds a formulation that a number of factors may cause operating results to fluctuate, referencing factors following the paragraph.
- Newer filing adds 'and' to the final bullet point: 'the ability of members of our senior management to manage our business and operations.' (this bullet is included in both filings, but the newer filing's formatting shows it with an 'and' conjunction).
- Removed:
- Older filing specifies the court as 'Superior Court of New Jersey, Chancery Division, Bergen County'; newer filing removes 'Chancery Division, Bergen County'.
- Older filing states 'NS may assert counterclaims against us'; newer filing changes this to 'NS has asserted counterclaims against us' (the 'may assert' wording is removed).
- Older filing states 'Litigation such as this lawsuit is inherently uncertain'; newer filing removes this sentence and replaces it with 'It is difficult to predict the outcome of any dispute'.
- Older filing lists additional bullet-point risk factors beginning with 'our dependency on third parties to formulate and manufacture our product candidates, as necessary' through 'the ability of members of our senior management to manage our business and operations.'; these bullets do not appear in the newer filing excerpt because the newer filing section appears truncated at 'our ability to successfully manufacture our product candidates in sufficient quantities and on a timely basis to meet clinical trial and potential commercial dema' and does not include the remaining bullets.
- Older filing includes a risk factor heading 'If we achieve our near-term product development milestones, we may not be able to manage any subsequent growth.' and its associated paragraph; newer filing excerpt does not include this risk factor because the excerpt ends before it appears.
- Reworded:
- Newer filing introductory paragraph adds 'and under Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026' after referencing the Form 10-K risk factors; older filing references only 'Item 1A of the Form 10-K'.
- Older filing describes the pending matter as 'litigation'; newer filing changes references to 'arbitration' in describing the process, outcome, and potential adverse effects.
- Older filing states 'NS may assert counterclaims against us'; newer filing states 'NS has asserted counterclaims against us'.
- Older filing sentence beginning 'Litigation such as this lawsuit is inherently uncertain' is replaced in newer filing with 'It is difficult to predict the outcome of any dispute'.
- Newer filing adds to the net losses risk factor: 'a number of factors may cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance' in the heading and introduces the bullet list with 'Other factors relating to our business that may contribute to these fluctuations include the following factors'; older filing does not include this introductory phrasing.
- Newer filing changes the second sentence of the net losses paragraph from 'expect to continue to incur substantial net losses for the foreseeable future' (both filings contain this) — no change detected.
- Both filings contain the same bullet list beginning with 'our need for additional capital'; newer filing includes 'and' before the final bullet listed in its excerpt, older filing shows the bullet list continuing through additional items.
- Notes:
- The newer filing excerpt appears truncated mid-sentence at 'to meet clinical trial and potential commercial dema' and does not include all risk factors that may follow; therefore removals of later bullet points and the 'subsequent growth' risk factor may be due to truncation rather than actual removal.
- The older filing excerpt also appears truncated shortly after the 'subsequent growth' risk factor begins, so it is not possible to determine whether that risk factor was removed in the newer filing or simply not visible due to excerpt length.
- The comparison is based solely on the provided excerpts; risk factors contained in the full 10-Q documents beyond these excerpts could not be compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 8 sells ($3M) — 2 selling insiders
Most recent open-market transaction: 2026-06-25. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CAPR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CAPR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,772,029
- Reported value $283,470,450
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CAPR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CAPR had 19,680,648 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CAPR had 33.9% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.92 days to cover at the same settlement.
- Reported short interest (shares) 19,680,648
- Short interest (% of shares outstanding) 33.9%
- Prior settlement (shares) 22,183,275
- Reported change -11.28%
- Days to cover (reported) 5.92
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- Pfizer (PFE)
- Solid Biosciences (SLDB)
- ReGenxbio (RGNX)
- Roche (RHHBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CAPR vs…
CAPRICOR THERAPEUTICS INC is found in…
CAPR ranks in…
Frequently asked questions
What does CAPRICOR THERAPEUTICS INC (CAPR) do?
Capricor Therapeutics is a biotechnology company focused on the development of cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with high unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy designed to address skeletal and cardiac muscle complications in DMD patients. The company also leverages a proprietary exosome platform, StealthX, to explore therapeutic applications for various conditions.
What sector is CAPRICOR THERAPEUTICS INC (CAPR) in?
CAPRICOR THERAPEUTICS INC (CAPR) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CAPRICOR THERAPEUTICS INC's (CAPR) competitors?
Notable peers of CAPRICOR THERAPEUTICS INC (CAPR) include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Solid Biosciences and ReGenxbio. This peer set is informational only — not financial advice.
Is CAPRICOR THERAPEUTICS INC (CAPR) overbought or oversold right now?
CAPRICOR THERAPEUTICS INC (CAPR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CAPR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.